M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn about the safety of giving M7824 to
patients with a certain type of colorectal cancer (Consensus Molecular Subtype 4 [CMS4]).
Researchers also want to learn if the study drug can help to control the disease.
This is an investigational study. M7824 is not FDA approved or commercially available. It is
currently being used for research purposes only.
The study doctor can explain how the study drug is designed to work.
Up to 59 participants will be enrolled in this study. All will take part at MD Anderson.